Skip to main content



24-01-2022 | Oncology | News | Article

Cutaneous irAEs linked to improved survival following ICI therapy

Cutaneous immune-related adverse events are associated with a reduced risk for death among cancer patients with immune checkpoint inhibitors, research suggests.

24-01-2022 | Rheumatology | News | Article

RA-ILD ‘commonly overlooked’ despite being linked to increased mortality risk

Interstitial lung disease affects a substantial proportion of patients with rheumatoid arthritis and is associated with reduced survival, but the condition is overlooked by clinicians, suggest results from a population-based study.

24-01-2022 | Diabetes | News | Article

BMI shows linear association with type 2 diabetes risk

BMI has a strong positive linear association with type 2 diabetes risk that generally does not vary by global region or ethnicity, show results of a dose-response meta-analysis.

21-01-2022 | Oncology | News | Article

ASCO/Ontario Health guideline on bone-modifying agents in breast cancer updated

Click through to find out what has changed

21-01-2022 | Diabetes | News | Article

Mortality threat receding in most high-income countries for people with diabetes

Mortality in people with diabetes is declining in most high-income countries, in many cases faster than in people without diabetes, researchers report.

21-01-2022 | Oncology | News | Article

Capecitabine-containing adjuvant regimen improves early breast cancer OS

Adjuvant treatment with a capecitabine-containing chemotherapy regimen could improve the overall survival of patients with early breast cancer, suggest long-term follow-up data from the phase 3 FinXX trial.

20-01-2022 | Oncology | News | Article

Sugemalimab shows promise for locally advanced, metastatic NSCLC

The PD-L1 inhibitor sugemalimab has shown potential both as a consolidation treatment option for inoperable, locally advanced non-small-cell lung cancer as well as in combination with chemotherapy for the first-line treatment of metastatic disease.

20-01-2022 | Rheumatology | News | Article

Rituximab-treated patients with ANCA-associated vasculitis may not respond to third COVID-19 vaccine dose

A third dose of the Pfizer–BioNTech vaccine gives rise to a neutralizing antibody response in the majority of people with ANCA-associated vasculitis, but those treated with rituximab are unlikely to respond, researchers report.

20-01-2022 | Neurology | News | Article

Plasma p-tau levels linked to cognitive decline in people with Lewy body dementia

Plasma levels of phosphorylated-tau proteins could serve as a biomarker for cognitive decline in individuals with dementia with Lewy bodies, say researchers who found an association between increasing levels of the proteins and more rapid decline in Mini-Mental State Examination scores over time.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

20-01-2022 | Diabetes | News | Article

No impact of diabetes, glycemic control on COVID-19 vaccine response

Findings from the COVAC-DM study suggest that people with type 1 or type 2 diabetes have an antibody response to COVID-19 vaccination that is similar to healthy individuals, with no association between glycemic control and antibody levels.

20-01-2022 | Rheumatology | News | Article

Similar response to heterologous vs homologous COVID-19 booster jab in rituximab-treated patients

It is possible for rituximab-treated patients with no response to two mRNA vaccines against SARS-CoV-2 to respond to a third dose, with similar response rates among those switching to a vector vaccine and those given a third dose of the same vaccine, research suggests.

19-01-2022 | Rheumatology | News | Article

Comorbidities may contribute to link between psoriatic arthritis and VTE risk

People with psoriatic arthritis have an increased risk for venous thromboembolism relative to the general population, and this association is likely to be related to underlying comorbidities, research suggests.

19-01-2022 | Diabetes | News | Article

Closed-loop benefits differ with high or low baseline HbA1c

Researchers find that the type of benefits people with type 1 diabetes gain from hybrid closed-loop insulin delivery differs according to their baseline glycemic control.

18-01-2022 | Diabetes | News | Article

Real-world data support HAPO link between LGA and raised maternal glycemia

Real-world data from Canada show that increasing maternal glycemia is associated with rising rates of large for gestational age births, confirming the results of the landmark HAPO trial.

18-01-2022 | Oncology | News | Article

Reassurance on radiotherapy use prior to ICI initiation

Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.

17-01-2022 | Rheumatology | News | Article

Weight gain during glucocorticoid use may signal treatment success in giant cell arteritis

Cumulative prednisone dose and effective disease control are both associated with increased BMI among patients with giant cell arteritis, post-hoc analysis of the GiACTA trial suggests.

17-01-2022 | Oncology | News | Article

BMI may be key to unlocking metformin NSCLC benefit

A post-hoc analysis of a randomized trial points to the benefit of adding metformin to an EGFR–tyrosine kinase inhibitor in advanced non-small-cell lung cancer patients with a BMI of at least 24 kg/m2.

14-01-2022 | Rheumatology | News | Article

JAK inhibitors may increase cholesterol in people with RA

Treatment with any of the five JAK inhibitors approved for use in rheumatoid arthritis in the USA, Europe, or Japan may lead to an increase in serum cholesterol levels, suggest results of a systematic review and network meta-analysis.

14-01-2022 | Diabetes | News | Article

Intensive glycemic control may prevent diabetic foot ulcers

Early intensive glycemic control may reduce the long-term risk for foot ulcers in people with type 1 diabetes, suggest data from the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study.

14-01-2022 | Oncology | News | Article

10-year cumulative false–positive mammography risk around 20%

Just under one in five women will experience at least one false–positive result during 10 years of biennial breast screening, population-based data from Norway show.